Please login to the form below

Not currently logged in
Email:
Password:

Storm Therapeutics strengthens its board

Professor Paul Workman joins as an independent director

Paul WorkmanDrug discovery group Storm Therapeutics has appointed Professor Paul Workman to join its board.

He said: “I am delighted to be joining the board of Storm and working with the company in this exploding area of biology.

“RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies.

“I look forward to working with the board to help guide Storm’s innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech.”

Workman currently serves The Institute of Cancer Research as its president and chief executive officer and has formerly served as head of the division of cancer therapeutics at Cancer Research UK.

Keith Blundy, CEO, Storm Therapeutics, said: “I am pleased to welcome Paul as indepdent director to Storm’s board.

“Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a world class cancer institute and being a founder of companies such as Piramed.

“We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”

14th November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...

Infographics